We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Expert Opinion / Commentary · December 19, 2022

2022 Top Story in Oncology: Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer—DESTINY-Breast04

Written by
Ilana Schlam MD
Sara M. Tolaney MD, MPH


Additional Info

  1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33.
  2. DeSantis CE, Ma J, Gaudet MM, et al. Breast Cancer Statistics, 2019. CA Cancer J Clin. 2019;69(6):438-451.
  3. Swain SM, Baselga J, Kim SB, et al. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2015;372(8):724-734.
  4. Cortés J, Kim S-B, Chung W-P, et al. Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022;386(12):1143-1154.
  5. Wolff AC, Hammond MEH, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36(20):2105-2122.
  6. Schettini F, Chic N, Brasó-Maristany F, et al. Clinical, Pathological, and PAM50 Gene Expression Features of HER2-Low Breast Cancer. NPJ Breast Cancer. 2021;7(1):1.
  7. Gampenrieder SP, Rinnerthaler G, Tinchon C, et al. Landscape of HER2-Low Metastatic Breast Cancer (MBC): Results From the Austrian AGMT_MBC-Registry. Breast Cancer Res. 2021;23(1):112.
  8. de Calbiac O, Lusque A, Mailliez A, et al. Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France. JAMA Netw Open. 2022;5(9):e2231170.
  9. Gianni L, Lladó A, Bianchi G, et al. Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin Oncol. 2010;28(7):1131-1137.
  10. Fehrenbacher L, Cecchini RS, Geyer CE Jr, et al. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+. J Clin Oncol. 2020;38(5):444-453.
  11. Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387(1):9-20.

Disclosure statements are available on the authors' profiles:

Further Reading